Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00022791" target="_blank" >RIV/00216224:14110/07:00022791 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
Original language description
Background In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. Aims The aim of this study is to show if these selected aberrations actas negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. Methods We have an increasing group of (recently 42) MM patients. Overall clinical characteristics of the patients at the start oftreatment: Average age 63.7 years (SD = 9.4), 57 % (24) of men. 12 % (5/42 pts) were in stage IA, 26 % (11/42 pts) were in stage IIA, 60 % (25/42 pts) were in stage IIIA and 2 % (1 patient) was in stage IIIB. 69 % (29/42 pts) were in fir
Czech name
Kompentzují "nové léky" vliv negativních cytogenetických prognostických markerů u mnohočetného myelomu?
Czech description
Předběžné výsledky, které naznačují, že nové léky možná kompenzují vliv klasických cytogentických negativních prognostických markerů u mnohočetného myelomu.
Classification
Type
D - Article in proceedings
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/LC06027" target="_blank" >LC06027: University Research Centre - Czech Myeloma Group</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2007
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
Blood reviews
ISBN
—
ISSN
0268-960X
e-ISSN
—
Number of pages
1
Pages from-to
131
Publisher name
Churchill Livingstone
Place of publication
Edinburgh
Event location
Budapest, Hungary
Event date
Aug 29, 2007
Type of event by nationality
EUR - Evropská akce
UT code for WoS article
—